nach oben

Eurasian Business Review

Erschienen in:

13.06.2018 | Regular Article

Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals

verfasst von: A. Carletto, A. Cicchetti, S. Coretti, V. Moramarco, M. Ruggeri

Erschienen in: Eurasian Business Review | Ausgabe 1/2019

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

The aim of this paper is to provide an empirical framework based on a discrete-time Markov chain to assess the costs and benefits of Performance Based Agreements (PBAs) for the reimbursement of pharmaceuticals. We provide an empirical testing using a case study referring to a treatment recently approved for reimbursement in Italy. The implementation of this framework is challenging for the agencies dealing with pricing and reimbursement decisions given the uncertainty associated with the treatment effectiveness and safety. On the other hand, empirical evidence shows that the awareness of the expected costs associated with different reimbursement schemes is necessary to inform decision-makers.

Vorheriger Artikel Product success implications of distant innovative knowledge

Nächster Artikel Interdisciplinarity: who reaps the benefits?

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

When probability of progression and death considerably changes over time, time-varying transition matrices should be applied at different model cycles, otherwise probabilities can be assumed to be constant in all model cycles.

Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osińska, B., Herholz, H., Wendykowska, K., et al. (2010). Risk sharing arrangements for pharmaceuticals: Potential considerations and recommendations for European payers. BMC Health Services Research, 10, 153. https://doi.org/10.1186/1472-6963-10-153.CrossRef

Antonanzas, F., Juarez-Castello, C., & Rodriguez-Ibeas, R. (2011). Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Economics, Policy, and Law, 6(3), 391–403. https://doi.org/10.1017/S1744133111000016.CrossRef

Associazione Italiana di Economia Sanitaria, gruppo di lavoro coordinato da Giovanni Fattore. (2009). Proposta di linee guida per la valutazione economica degli interventi sanitari. Politiche sanitarie, 10(2), 91–99.

Atella, V. (1999). Drug cost containment policies in Italy: Are they really effective in the long-run?-The case of minimum reference price. Health Policy, 50(3), 197–218.CrossRef

Barros, P. P. (2011). The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Economics, 20(4), 461–470. https://doi.org/10.1002/hec.CrossRef

Caro, J. J., Briggs, A. H., Sieber, U., & Kuntz, K. M. (2012). Modeling good research practices—overview: A report of the ISPOR-SMDM modeling good research practices task force-1. Value in Health, 15, 796–803.CrossRef

Claxton, K. (2007). OFT, VBP: QED? Health Economics, 558, 545–558. https://doi.org/10.1002/hec.CrossRef

Claxton, K., Briggs, A., Buxton, M. J., Culyer, A. J., McCabe, C. J., Walker, S., et al. (2008). Value based pricing for NHS drugs: An opportunity not to be missed? BMJ British Medical Journal, 336, 251–254.CrossRef

Claxton, K., Cohen, J. T., & Neumann, P. J. (2005). When is evidence sufficient? Health Affairs (Project Hope), 24(1), 93–101. https://doi.org/10.1377/hlthaff.24.1.93.CrossRef

de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21), 1995–2005. https://doi.org/10.1056/NEJMoa1014618.CrossRef

Espín, J., Rovira, J., & García, L. (2011). Experiences and impact of European risk-sharing schemes focusing on oncology medicines. EmiNet, Andalusian School of Public Health.

Galizzi, M. M., Ghislandi, S., & Miraldo, M. (2011). Effects of reference pricing in pharmaceutical markets: A review. PharmacoEconomics, 29(1), 17–33. https://doi.org/10.2165/11537860-000000000-000000000.CrossRef

Garattini, L., & Casadei, G. (2011). Risk sharing agreements: What lessons from Italy? International Journal of Technology Assessment in Health Care, 27(2), 169–172. https://doi.org/10.1017/S0266462311000079.CrossRef

Garattini, L., & van de Vooren, K. (2011). Budget impact analysis in economic evaluation: A proposal for a clearer definition. European Journal of Health Economics, 12, 499. https://doi.org/10.1007/s10198-011-0348-5.CrossRef

Garrison, L. P., Towse, A., Briggs, A., de Pouvourville, G., Grueger, J., Mohr, P. E., et al. (2013). Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value in Health, 16(5), 703–719. https://doi.org/10.1016/j.jval.2013.04.011.CrossRef

Gavious, A., Greenberg, D., Hammerman, A., & Segev, E. (2014). Impact of a financial risk-sharing scheme on budget-impact estimations: A game-theoretic approach. The European Journal of Health Economics, 15(5), 553–561. https://doi.org/10.1007/s10198-013-0544-6.CrossRef

Ghislandi, S., Krulichova, I., & Garattini, L. (2005). Pharmaceutical policy in Italy: Towards a structural change? Health Policy, 72(1), 53–63.CrossRef

Hutton, J., Trueman, P., & Henshall, C. (2007). Coverage with evidence development: an examination of conceptual and policy issues. International Journal of Technology Assessment in Health Care, 23(4), 425–432. https://doi.org/10.1017/S0266462307070651.CrossRef

Jommi, C., Costa, E., Michelon, A., Pisacane, M., & Scroccaro, G. (2013). Multi-tier drugs assessment in a decentralised health care system. The Italian case-study. Health Policy, 112(3), 241–247.

Jommi, C., & Minghetti, P. (2015). Pharmaceutical pricing policies in Italy. In Z.-U.-D. Babar (Ed.), Pharmaceutical prices in the 21st century (pp. 131–150). New York: Springer.

Levaggi, R. (2014). Pricing schemes for new drugs: A welfare analysis. Social Science and Medicine, 102, 69–73. https://doi.org/10.1016/j.socscimed.2013.11.048.CrossRef

Lilico, A. (2003). Risk-sharing pricing models in the distribution of pharmaceuticals. Europe Economics Staff Working Paper (No. 1).

Mahjoub, R., Odegaard, F., & Zaric, G. S. (2014). Health-based pharmaceutical pay-for-performance risk-sharing agreements. Journal of the Operational Research Society, 65(4), 588–604. https://doi.org/10.1057/jors.2013.106.CrossRef

McCabe, C. J., Stafinski, T., Edlin, R., & Menon, D. (2010). Access with evidence development schemes: A framework for description and evaluation. PharmacoEconomics, 28(2), 143–152. https://doi.org/10.2165/11530850-000000000-00000.CrossRef

Menon, D., McCabe, C. J., Stafinski, T., & Edlin, R. (2010). Principles of design of access with evidence development approaches: A consensus statement from the Banff Summit. PharmacoEconomics, 28(2), 109–111. https://doi.org/10.2165/11530860-000000000-00000.CrossRef

Mohr, P. E., & Tunis, S. R. (2010). Access with evidence development: The US experience. PharmacoEconomics, 28(2), 153–162. https://doi.org/10.2165/11531050-000000000-00000.CrossRef

Neumann, P. J., Kamae, M. S., & Palmer, J. A. (2008). Medicare’s national coverage decisions for technologies, 1999-2007. Health Affairs, 27(6), 1620–1631. https://doi.org/10.1377/hlthaff.27.6.1620.CrossRef

Paris, V., & Belloni, A. (2013). Value in pharmaceutical pricing. OECD Health Working Paper No. 63. Paris, France. https://doi.org/10.1787/5k43jc9v6knx-en.

Peiró, R. P., Ferrandiz, J. M., Sussex, J., Towse, A., & Economics, H. (2011). Literature review on patient access schemes, flexible pricing schemes and risk sharing agreements for medicines. In PPRI Conference, 29–30 September 2011. Vienna, Austria.

Russo, P., Mennini, F. S., Siviero, P. D., & Rasi, G. (2010). Time to market and patient access to new oncology products in Italy: A multistep pathway from European context to regional health care providers. Annals of Oncology, 21(10), 2081–2087. https://doi.org/10.1093/annonc/mdq097.CrossRef

Stafinski, T., Mccabe, C. J., & Menon, D. (2010). Funding the unfundable. PharmacoEconomics, 28(2), 113–142.CrossRef

Trueman, P., Grainger, D. L., & Downs, K. E. (2010). Coverage with evidence development: Applications and issues. International Journal of Technology Assessment in Health Care, 26(1), 79–85. https://doi.org/10.1017/S0266462309990882.CrossRef

UK Department of Health. Patient access schemes and flexible pricing: statement of outcomes from the review of the pricing flexibility measures under Chapter 6 of the 2009 PPRS. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/146829/dh_132794.pdf. Accessed August 28, 2014.

Walker, S., Sculpher, M. J., Claxton, K., & Palmer, S. (2012). Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value in Health, 15(3), 570–579. https://doi.org/10.1016/j.jval.2011.12.013.CrossRef

Williamson, S. (2010). Patient access schemes for high-cost cancer medicines. The lancet Oncology, 11(2), 111–112. https://doi.org/10.1016/S1470-2045(09)70402-4.CrossRef

Wonder, M., Backhouse, M. E., & Sullivan, S. D. (2012). Australian managed entry scheme: a new manageable process for the reimbursement of new medicines? Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 15(3), 586–590. https://doi.org/10.1016/j.jval.2012.02.004.CrossRef

Zaric, G. S., & O’brien, B. J. (2005). Analysis of a pharmaceutical risk sharing agreement based on the purchaser’s total budget. Health Economics, 14(8), 793–803. https://doi.org/10.1002/hec.976.CrossRef

Zhang, H., Zaric, G. S., & Huang, T. (2011). Optimal design of a pharmaceutical price-volume agreement under asymmetric information about expected market size. Production and Operations Management, 20(3), 334–346. https://doi.org/10.1111/j.1937-5956.2011.01219.CrossRef

Titel: Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals
verfasst von: A. Carletto
A. Cicchetti
S. Coretti
V. Moramarco
M. Ruggeri
Publikationsdatum: 13.06.2018
Verlag: Springer International Publishing
Erschienen in: Eurasian Business Review / Ausgabe 1/2019
Print ISSN: 1309-4297
Elektronische ISSN: 2147-4281
DOI: https://doi.org/10.1007/s40821-018-0107-y

Springer Professional

Abstract

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft"

Springer Professional "Wirtschaft+Technik"

Weitere Artikel der Ausgabe 1/2019

Productivity, technological innovations and broadband connectivity: firm-level evidence for ten European countries

History friendly models: retrospective and future perspectives

Product success implications of distant innovative knowledge

Interdisciplinarity: who reaps the benefits?

How does national culture affect corporate risk-taking?